Kymera Therapeutics (KYMR) shares were down over 1% in recent Thursday trading after the company reported a Q3 loss, while its collaboration revenue decreased year-over-year and fell short of analyst expectations.
The company reported a Q3 net loss of $0.82 per diluted share, compared with a loss of $0.90 a year earlier.
Analysts polled by Capital IQ expected a $0.84 loss.
Collaboration revenue for the quarter ended Sept. 30 fell to $3.7 million from $4.7 million a year earlier.
Analysts surveyed by Capital IQ expected $10.3 million.
In August, the company raised about $247 million in net proceeds from an equity offering. Kymera said Thursday it extended its cash runway into mid-2027 with the proceeds.
Price: 46.97, Change: -0.70, Percent Change: -1.47
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。